|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
IL152275A0
(en)
|
2000-04-25 |
2003-05-29 |
Icos Corp |
Inhibitors of human phosphatidyl-inositol 3-kinase delta
|
|
GB0119865D0
(en)
*
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
GB2405870B
(en)
*
|
2001-08-14 |
2005-07-06 |
Cancer Rec Tech Ltd |
DNA-PK inhibitors
|
|
GB0119863D0
(en)
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
WO2003022271A1
(fr)
*
|
2001-09-05 |
2003-03-20 |
Eisai C0. Ltd. |
Inhibiteur d'activation lymphocytaire et remede pour maladie auto-immune
|
|
US7049313B2
(en)
|
2002-02-25 |
2006-05-23 |
Kudos Pharmaceuticals Ltd. |
ATM inhibitors
|
|
MY156407A
(en)
|
2002-02-28 |
2016-02-26 |
Novartis Ag |
5-phenylthiazole derivatives and use as p13 kinase inhibitors
|
|
EP2311818B1
(en)
*
|
2002-02-28 |
2013-01-16 |
Novartis AG |
Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
|
|
NZ538420A
(en)
*
|
2002-08-16 |
2007-06-29 |
Kinacia Pty Ltd |
Inhibition of phosphoinositide 3-kinase beta
|
|
CN100430389C
(zh)
*
|
2002-08-16 |
2008-11-05 |
阿斯利康(瑞典)有限公司 |
抑制磷酸肌醇3-激酶β
|
|
AU2003265585B2
(en)
*
|
2002-08-26 |
2008-07-03 |
Takeda Pharmaceutical Company Limited |
Calcium receptor modulating compound and use thereof
|
|
CA2508601A1
(en)
|
2002-12-06 |
2004-06-24 |
Warner-Lambert Company Llc |
Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
|
|
GB0305152D0
(en)
*
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
|
EP1611119A1
(en)
*
|
2003-04-03 |
2006-01-04 |
Semafore Pharmaceuticals, Inc. |
Pi-3 kinase inhibitor prodrugs
|
|
CA2522595A1
(en)
|
2003-04-03 |
2004-10-28 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
JP2006526608A
(ja)
*
|
2003-06-05 |
2006-11-24 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド
|
|
EP1636212B1
(en)
*
|
2003-06-05 |
2007-06-27 |
Warner-Lambert Company LLC |
Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents
|
|
US20040259926A1
(en)
*
|
2003-06-05 |
2004-12-23 |
Bruendl Michelle M. |
3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
|
|
US7429660B2
(en)
|
2003-08-13 |
2008-09-30 |
Kudos Pharmaceuticals Limited |
ATM inhibitors
|
|
CA2536930A1
(en)
*
|
2003-09-04 |
2005-03-17 |
Warner-Lambert Company Llc |
Halo substituted benzo`b! thiophenes with pi3k inhibitory activity as therapeutic agents
|
|
JP2007509924A
(ja)
*
|
2003-10-31 |
2007-04-19 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
ホスホイノシチド−３−キナーゼ（ｐｉ３ｋ）阻害剤としてのピリミジン
|
|
EP1716151A1
(en)
*
|
2004-01-26 |
2006-11-02 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
ES2605792T3
(es)
|
2004-05-13 |
2017-03-16 |
Icos Corporation |
Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
|
|
CN1300163C
(zh)
*
|
2004-06-23 |
2007-02-14 |
南京大学 |
3－羟基色原酮糖苷及其制法和用途
|
|
KR20070059156A
(ko)
|
2004-09-20 |
2007-06-11 |
쿠도스 파마슈티칼스 리미티드 |
Ｄｎａ－ｐｋ 억제제
|
|
WO2006085067A1
(en)
|
2005-02-09 |
2006-08-17 |
Kudos Pharmaceuticals Limited |
Atm inhibitors
|
|
AR054438A1
(es)
|
2005-04-15 |
2007-06-27 |
Kudos Pharm Ltd |
Inhibidores de adn -pk
|
|
WO2007127366A2
(en)
|
2006-04-25 |
2007-11-08 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
|
AU2007262670B2
(en)
*
|
2006-06-22 |
2012-12-20 |
Prana Biotechnology Limited |
Method of treatment of glioma brain tumour
|
|
WO2008102932A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Biobud Co., Ltd. |
Compositions for treating hyperproliferative vascular disorders and cancers
|
|
EP2157092A4
(en)
|
2007-04-11 |
2011-04-13 |
Ajinomoto Kk |
Remedy for diabetes
|
|
WO2008150827A1
(en)
*
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
WO2009008991A2
(en)
*
|
2007-07-06 |
2009-01-15 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health |
Dna-pkcs modulates energy regulation and brain function
|
|
BRPI0906805A2
(pt)
*
|
2008-01-25 |
2015-07-14 |
Astrazeneca Ab |
Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação
|
|
WO2009129372A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Shenogen Pharma Group Ltd. |
Compounds and methods for treating estrogen receptor-related diseases
|
|
KR101679089B1
(ko)
|
2008-09-29 |
2016-11-23 |
서트리스 파마슈티컬즈, 인코포레이티드 |
시르투인 조절제로서의 크로메논 유사체
|
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
SG10201703911XA
(en)
|
2008-11-13 |
2017-06-29 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
EP2448932B1
(fr)
|
2009-07-02 |
2014-03-05 |
Sanofi |
Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4-(3h)-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
|
|
WO2011001114A1
(fr)
|
2009-07-02 |
2011-01-06 |
Sanofi-Aventis |
Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
|
|
JP5663571B2
(ja)
|
2009-07-02 |
2015-02-04 |
サノフイ |
新規２，３−ジヒドロ−１Ｈ−イミダゾ｛１，２−ａ｝ピリミジン−５−オン誘導体、これらの調製およびこれらの薬学的使用
|
|
RU2561130C2
(ru)
|
2009-07-02 |
2015-08-20 |
Санофи |
НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
|
|
US8691829B2
(en)
|
2009-07-21 |
2014-04-08 |
Gilead Calistoga Llc |
Treatment of liver disorders with PI3K inhibitors
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
IT1403156B1
(it)
|
2010-12-01 |
2013-10-04 |
Università Degli Studi Di Torino |
Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
|
|
FR2969612B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
|
|
HUE024504T2
(en)
|
2010-12-23 |
2016-01-28 |
Sanofi Sa |
Pyrimidine derivatives, a process for their preparation and their use in medicine
|
|
FR2969613B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
|
|
PL2658844T3
(pl)
|
2010-12-28 |
2017-04-28 |
Sanofi |
Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
|
|
ES2648154T3
(es)
|
2012-01-26 |
2017-12-28 |
Daiichi Sankyo Company, Limited |
Derivado de cromona que tiene un efecto promotor de la osteogénesis
|
|
MX354074B
(es)
*
|
2012-02-10 |
2018-02-12 |
Ptc Therapeutics Inc |
Compuestos para tratar la atrofia muscular espinal.
|
|
JP6092264B2
(ja)
|
2012-03-01 |
2017-03-08 |
ピーティーシー セラピューティクス， インコーポレイテッド |
脊髄性筋委縮症を処置するための化合物
|
|
CN106146506A
(zh)
|
2012-03-05 |
2016-11-23 |
吉利德卡利斯托加公司 |
(s)‑2‑(1‑(9h‑嘌呤‑6‑基氨基)丙基)‑5‑氟‑3‑苯基喹唑啉‑4(3h)‑酮的多晶型物
|
|
CN104470909B
(zh)
|
2012-03-23 |
2018-04-24 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩的化合物
|
|
ITMI20120514A1
(it)
*
|
2012-03-29 |
2013-09-30 |
Cnr Consiglio Naz Delle Ric Erche |
Agente terapeutico per il trattamento dei vasi sanguigni
|
|
FR2992314B1
(fr)
|
2012-06-22 |
2015-10-16 |
Sanofi Sa |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
|
|
US10195202B2
(en)
|
2013-12-19 |
2019-02-05 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount of RNA transcripts
|
|
WO2015095605A1
(en)
|
2013-12-20 |
2015-06-25 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
|
EP3083630B1
(en)
|
2013-12-20 |
2019-08-21 |
Gilead Calistoga LLC |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
|
AU2015274696B2
(en)
|
2014-06-13 |
2018-09-27 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
EP3298017B1
(en)
*
|
2015-05-20 |
2019-08-14 |
H. Hoffnabb-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
EP4249472A3
(en)
|
2015-05-30 |
2023-12-13 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
MX391850B
(es)
|
2015-12-10 |
2025-03-19 |
Ptc Therapeutics Inc |
Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
|
|
MX382300B
(es)
|
2015-12-17 |
2025-03-13 |
Alonbio Ltd |
Moléculas pequeñas para inhibir la actividad de quimiocinas y/o el crecimiento de células cancerosas.
|
|
EP3390378B1
(en)
|
2015-12-17 |
2022-03-30 |
AlonBio Ltd. |
Small molecules against cancer
|
|
US11091483B2
(en)
*
|
2016-08-12 |
2021-08-17 |
Madera Therapeutics, LLC |
Protein kinase regulators
|
|
MX2019005588A
(es)
|
2016-11-28 |
2019-10-15 |
Ptc Therapeutics Inc |
Metodos para modular corte y empalme de arn.
|
|
JP2020506904A
(ja)
|
2017-01-27 |
2020-03-05 |
シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド |
キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
|
|
CA3066224A1
(en)
|
2017-06-05 |
2018-12-13 |
Ptc Therapeutics Inc. |
Compounds for treating huntington's disease
|
|
KR20200017476A
(ko)
|
2017-06-14 |
2020-02-18 |
피티씨 테라퓨틱스, 인크. |
Rna 스플라이싱의 변경 방법
|
|
MX2019015580A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
|
US11382918B2
(en)
|
2017-06-28 |
2022-07-12 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's Disease
|
|
JP7399870B2
(ja)
|
2018-03-27 |
2023-12-18 |
ピーティーシー セラピューティクス， インコーポレイテッド |
ハンチントン病を処置するための化合物
|
|
KR20210038845A
(ko)
|
2018-06-27 |
2021-04-08 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료를 위한 헤테로아릴 화합물
|
|
HUE068060T2
(hu)
|
2018-06-27 |
2024-12-28 |
Ptc Therapeutics Inc |
Heterociklikus és heteroaril vegyületek Huntington-kór kezelésére
|
|
US11685746B2
(en)
|
2018-06-27 |
2023-06-27 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating Huntington's disease
|
|
CN109748914B
(zh)
*
|
2018-12-29 |
2021-05-25 |
上海珂臻医药科技有限公司 |
吡啶并嘧啶类化合物及其应用
|
|
EP3759074B1
(en)
|
2019-05-15 |
2025-01-01 |
AlonBio Ltd. |
Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
|
|
AR121719A1
(es)
|
2020-04-03 |
2022-06-29 |
Petra Pharma Corp |
Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
|
|
CN111533721B
(zh)
*
|
2020-05-15 |
2022-04-26 |
浙江大学 |
苯并吡喃酮或喹啉酮类化合物及其应用
|
|
WO2021247859A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Yumanity Therapeutics, Inc. |
Pyridopyrimidines and methods of their use
|
|
US20240166617A1
(en)
*
|
2021-02-01 |
2024-05-23 |
Geode Therapeutics Inc. |
Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
|
|
TW202309003A
(zh)
|
2021-05-03 |
2023-03-01 |
美商佩特拉製藥公司 |
用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
|
|
KR20240014065A
(ko)
|
2021-05-27 |
2024-01-31 |
페트라 파마 코포레이션 |
암의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
|
|
TW202329930A
(zh)
|
2021-09-30 |
2023-08-01 |
美商佩特拉製藥公司 |
用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
|
|
US20250084048A1
(en)
*
|
2021-10-07 |
2025-03-13 |
Relay Therapeutics, Inc. |
Pi3k-alpha inhibitors and methods of use thereof
|
|
WO2025136936A1
(en)
*
|
2023-12-19 |
2025-06-26 |
Merck Sharp & Dohme Llc |
Agonists of trem2 activity
|